Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Assets (2017 - 2025)

Historic Assets for Vistagen Therapeutics (VTGN) over the last 13 years, with Q4 2025 value amounting to $65.1 million.

  • Vistagen Therapeutics' Assets fell 2952.21% to $65.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $65.1 million, marking a year-over-year decrease of 2952.21%. This contributed to the annual value of $84.3 million for FY2025, which is 3179.22% down from last year.
  • Vistagen Therapeutics' Assets amounted to $65.1 million in Q4 2025, which was down 2952.21% from $80.9 million recorded in Q3 2025.
  • Vistagen Therapeutics' 5-year Assets high stood at $131.1 million for Q4 2023, and its period low was $15.0 million during Q2 2023.
  • Over the past 5 years, Vistagen Therapeutics' median Assets value was $82.6 million (recorded in 2025), while the average stood at $77.4 million.
  • As far as peak fluctuations go, Vistagen Therapeutics' Assets soared by 177587.79% in 2021, and later tumbled by 7440.25% in 2023.
  • Vistagen Therapeutics' Assets (Quarter) stood at $90.5 million in 2021, then tumbled by 67.19% to $29.7 million in 2022, then surged by 341.18% to $131.1 million in 2023, then fell by 29.57% to $92.3 million in 2024, then fell by 29.52% to $65.1 million in 2025.
  • Its Assets stands at $65.1 million for Q4 2025, versus $80.9 million for Q3 2025 and $68.9 million for Q2 2025.